Dr. Heather J. Bax is a Postdoctoral Research Fellow at St John’s Institute of Dermatology, King’s College London. She trained at GlaxoSmithKline as an industrial placement and undergraduate project student supporting drug discovery for asthma and allergic inflammation. She completed her PhD in Professor Hannah Gould’s laboratory, King’s College London, focusing on the interaction between IgE antibodies and mast cells in the context of allergic diseases.
As a Postdoctoral Research Associate in Professor Sophia Karagiannis’ laboratory, King’s College London, Dr. Bax undertook multidisciplinary research on the ground-breaking preclinical development of the first-in-class IgE antibody, MOv18 IgE, for the treatment of folate receptor alpha (FRα)-expressing ovarian cancers. In this role, she established and implemented several clinical trial assays to support the now successfully completed first-in-man, Phase 1 clinical trial of MOv18 IgE (ClinicalTrials.gov Identifier: NCT02546921). She also led the preclinical studies of CSPG4 IgE, another IgE therapeutic candidate targeting melanoma.
Dr. Bax currently supports a translational research program funded by the King’s College London spinout Epsilogen Ltd (formerly IGEM Therapeutics Ltd.), the first immuno-oncology company focusing on IgE immunotherapies for cancer. Leading a team of two postdoctoral researchers and working closely with colleagues at Epsilogen Ltd., she oversees several research studies focusing on the next generation of IgE-based antibodies for the treatment of solid tumors.
